Queen's Award Received in 2021 ISO 9001 Certified Delivered over 1,000,000 bio-reagents to life science researchers Trusted by Life Science Communities
Cart summary

You have no items in your shopping cart.

Palosuran

SKU: orb1224746

Description

A potent and specific antagonist of human Urotensin (UT) receptor; inhibits 125I-U-II binding to human UT receptors in membrane preparations from CHO cells carrying the human UT receptors with IC50 of 3.6 nM; prevents the development of acute renal failure and the histological consequences of ischemia in rats.Ischemia Discontinued(In Vitro):Palosuran (8 h) inhibits 125I-U-II binding to human UT receptor, with IC50s of 46.2 nM on TE 671 cells and 86 nM on recombinant CHO cells.Palosuran inhibits Ca2+ mobilization in response to human U-II in CHO cells expressing human and rat UT receptor with IC50s of 17 and >10000 nM, respectively.Palosuran (0.12-10000 nM; 20 min) inhibits human U-II induced MAPK phosphorylation in a dose-dependent manner in recombinant CHO cells, with an IC50 of 150 nM.(In Vivo):ACT-058362 (10 mg/kg/h; i.v.) fully prevents the decrease in renal blood flow after ischemia in rats without decreasing blood pressure.Palosuran (300 mg/kg/d; p.o. for 16 weeks) improves the survival, increases insulin, and slows the increase in glycemia, glycosylated hemoglobin, and serum lipids in streptozotocin-induced diabetic rats.

Images & Validation

Key Properties

CAS Number540769-28-6
MW418.5313
Purity>98% (HPLC)
FormulaC25H30N4O2
SMILESO=C(NC1=CC(C)=NC2=CC=CC=C12)NCCN3CCC(CC4=CC=CC=C4)(O)CC3
TargetUrotensin Receptor
SolubilityDMSO: ≥ 30 mg/mL

Bioactivity

In Vivo
ACT-058362 (10 mg/kg/h; i. v.) fully prevents the decrease in renal blood flow after ischemia in rats without decreasing blood pressure. Palosuran (300 mg/kg/d; p.o. for 16 weeks) improves the survival, increases insulin, and slows the increase in glycemia, glycosylated hemoglobin, and serum lipids in streptozotocin-induced diabetic rats. Animal model: Male Wistar rats with renal ischemia and reperfusion. Dosage: 20 mg/kg/h for 135 min. Administration: I. v. (continuous infusion) for 135 min. Result: Restored renal blood flow to baseline values at 30 min after reperfusion and by 60 min increased renal blood flow by 12% above baseline values.
In Vitro
Palosuran (8 h) inhibits 125I-U-II binding to human UT receptor, with IC50s of 46.2 nM on TE 671 cells and 86 nM on recombinant CHO cells. Palosuran inhibits Ca2+ mobilization in response to human U-II in CHO cells expressing human and rat UT receptor with IC50s of 17 and >10000 nM, respectively. Palosuran (0.12-10000 nM; 20 min) inhibits human U-II induced MAPK phosphorylation in a dose-dependent manner in recombinant CHO cells, with an IC50 of 150 nM.

Storage & Handling

StorageStorage temperature: -20°C. Stability: ≥ 2 years
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

ACT058362 | ACT 058362 | ACT-058362

Similar Products

  • Palosuran [orb1705555]

    99.65% (May vary between batches)

    540769-28-6

    418.53

    C25H30N4O2

    5 mg, 2 mg, 10 mg, 25 mg, 50 mg, 100 mg, 1 ml x 10 mM (in DMSO)
  • Palosuran hydrochloride 540769-28-6(free base) [orb1302650]

    99.75% (May vary between batches)

    454.99

    C25H31ClN4O2

    1 mg, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 1 ml x 10 mM (in DMSO)
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Protocol Information

Available Sizes

Select a size below

2 mg
$ 170.00
5 mg
$ 310.00
10 mg
$ 430.00
25 mg
$ 690.00
50 mg
$ 980.00
100 mg
$ 1,380.00
500 mg
$ 2,740.00